SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
141 hedge funds and large institutions have $1.82B invested in SpringWorks Therapeutics in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 68 increasing their positions, 36 reducing their positions, and 19 closing their positions.
89% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 36
7% more capital invested
Capital invested by funds: $1.7B → $1.82B (+$120M)
5.34% more ownership
Funds ownership: 106.03% → 111.37% (+5.3%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
5% less funds holding
Funds holding: 148 → 141 (-7)
20% less call options, than puts
Call options by funds: $951K | Put options by funds: $1.2M
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$28M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$26.9M |
| 3 |
BlackRock
New York
|
+$26.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$34.2M |
| 2 |
PA
Perceptive Advisors
New York
|
-$14.2M |
| 3 |
Barclays
London,
United Kingdom
|
-$14.1M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$13.3M |
| 5 |
O
OrbiMed
New York
|
-$8.42M |
SWTX Hedge Fund Activity: Q2 2023 in Review
141 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q2 2023, worth a combined $1.82B — up 7% from $1.7B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of SWTX and 13 opened new positions — a net loss of 6 holders — while 36 trimmed existing stakes and 68 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $28M. The largest seller was Woodline Partners, cutting an estimated $34.2M.
- 141 institutional investors held SpringWorks Therapeutics (SWTX) as of Q2 2023, down from 148 in Q1 2023.
- Funds reported $1.82B of SpringWorks Therapeutics stock for Q2 2023, up 7% quarter-over-quarter.
- 13 funds opened new SpringWorks Therapeutics positions in Q2 2023 and 19 closed out, a net change of -6 holders.
- The largest SpringWorks Therapeutics buyer in Q2 2023 was T. Rowe Price Associates, an estimated $28M added.
- The largest SpringWorks Therapeutics seller in Q2 2023 was Woodline Partners, an estimated $34.2M sold.
Based on aggregated 13F filings for Q2 2023.